Publication Cover
Expert Review of Precision Medicine and Drug Development
Personalized medicine in drug development and clinical practice
Volume 3, 2018 - Issue 1
86
Views
0
CrossRef citations to date
0
Altmetric
Review

Circulating tumor DNA: an important tool in precision medicine for lymphoma

, , , &
Pages 11-21 | Received 28 Oct 2017, Accepted 30 Nov 2017, Published online: 06 Dec 2017
 

ABSTRACT

Introduction: The presence of circulating tumor DNA (ctDNA) was demonstrated years ago in solid tumors and represents a promising technology for the non-invasive management of cancers. In the case of Hodgkin’s lymphomas (HL) and non-Hodgkin’s lymphomas (NHL), idiotype specific tumor markers are too cumbersome for general use, but recent studies have demonstrated the presence of ctDNA easily extractable from plasma, making it possible to reveal molecular profiles similar to the primary tumor.

Areas covered: In this review, the authors present the concept of liquid biopsy, the latest in technological advances enabling the simple, rapid and reproducible analysis of ctDNA in patients with lymphomas. The authors summarize the results that have demonstrated the clinical pertinence of this tool in establishing diagnostic and prognostic stratification and allowing minimal residual disease (MRD) follow-up in patients with HL and NHL, with a special focus on diffuse large B-cell lymphoma.

Expert commentary: ctDNA analysis as the main tool to quantify somatic mutations, represents a major technological leap in the non-invasive management of lymphomas. At the dawn of the era of personalized medicine, this technology enables follow-up and treatment adaptation in real time, as well as early detection of refractory or relapsed diseases and resistance to therapeutics.

Declaration of Interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.